Your browser is no longer supported. Please, upgrade your browser.
Settings
SAVA [NASD]
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own5.20% Shs Outstand37.72M Perf Week-43.65%
Market Cap2.85B Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float37.41M Perf Month-18.62%
Income-8.70M PEG- EPS next Q-0.13 Inst Own27.80% Short Float11.82% Perf Quarter48.57%
Sales- P/S- EPS this Y8.80% Inst Trans0.61% Short Ratio1.49 Perf Half Y250.81%
Book/sh7.45 P/B9.33 EPS next Y-1000.00% ROA-8.10% Target Price94.20 Perf Year2086.48%
Cash/sh6.87 P/C10.12 EPS next 5Y- ROE-8.30% 52W Range2.78 - 146.16 Perf YTD919.50%
Dividend- P/FCF- EPS past 5Y35.40% ROI- 52W High-52.43% Beta1.14
Dividend %- Quick Ratio107.10 Sales past 5Y- Gross Margin- 52W Low2401.08% ATR17.11
Employees11 Current Ratio107.10 Sales Q/Q- Oper. Margin- RSI (14)39.53 Volatility27.43% 16.74%
OptionableYes Debt/Eq0.00 EPS Q/Q-99.00% Profit Margin- Rel Volume8.44 Prev Close103.35
ShortableYes LT Debt/Eq0.00 EarningsApr 21 BMO Payout- Avg Volume2.96M Price69.53
Recom2.00 SMA20-32.47% SMA50-15.17% SMA20067.31% Volume25,020,396 Change-32.72%
Jul-15-21Downgrade Cantor Fitzgerald Overweight → Neutral $100
Jul-07-21Reiterated Maxim Group Buy $80 → $190
Apr-27-21Initiated B. Riley Securities Buy $78
Feb-16-21Reiterated H.C. Wainwright Buy $20 → $66
Oct-23-20Initiated Cantor Fitzgerald Overweight $24
Sep-23-20Upgrade H.C. Wainwright Neutral → Buy $20
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Jul-31-21 09:15AM  
Jul-29-21 03:38PM  
03:30PM  
09:53AM  
09:53AM  
05:44AM  
Jul-28-21 01:08PM  
Jul-27-21 04:19PM  
03:53PM  
Jul-26-21 08:30AM  
Jul-23-21 04:53PM  
04:20PM  
Jul-22-21 06:52AM  
05:36AM  
Jul-21-21 03:39PM  
08:30AM  
Jul-20-21 04:52PM  
08:12AM  
Jul-16-21 01:56PM  
Jul-12-21 09:07PM  
05:25PM  
Jul-05-21 06:06AM  
Jul-01-21 06:00AM  
Jun-26-21 07:38AM  
Jun-24-21 07:18AM  
Jun-23-21 05:35PM  
03:07PM  
11:08AM  
Jun-22-21 10:22AM  
08:38AM  
Jun-21-21 04:32PM  
04:10PM  
11:45AM  
08:30AM  
Jun-18-21 05:50PM  
Jun-17-21 04:01PM  
Jun-16-21 06:13AM  
Jun-14-21 08:30AM  
Jun-12-21 09:15AM  
Jun-11-21 06:45AM  
Jun-09-21 08:28AM  
Jun-08-21 03:16PM  
10:09AM  
Jun-07-21 02:00PM  
01:48PM  
May-25-21 07:50AM  
May-24-21 08:30AM  
May-21-21 04:10PM  
04:05PM  
May-18-21 12:30PM  
May-12-21 02:15PM  
07:30AM  
May-10-21 03:57PM  
08:30AM  
Apr-27-21 01:08PM  
08:30AM  
Apr-26-21 08:30AM  
Apr-22-21 10:26PM  
Apr-21-21 08:30AM  
Apr-16-21 05:50PM  
Apr-07-21 06:06AM  
Mar-24-21 11:30AM  
Mar-23-21 08:30AM  
Mar-21-21 06:18AM  
Mar-19-21 08:34PM  
11:38AM  
Mar-18-21 06:16AM  
Mar-17-21 03:37PM  
Mar-15-21 07:02AM  
Mar-12-21 08:25AM  
Mar-10-21 09:14AM  
Mar-09-21 09:00AM  
Mar-08-21 11:30AM  
11:00AM  
08:30AM  
Mar-06-21 06:44AM  
Feb-26-21 06:01PM  
09:47AM  
08:40AM  
Feb-23-21 08:30AM  
Feb-22-21 12:19PM  
08:30AM  
Feb-18-21 07:25PM  
Feb-16-21 04:16PM  
Feb-15-21 05:35AM  
Feb-13-21 06:06AM  
Feb-12-21 07:00PM  
05:08PM  
Feb-11-21 11:00AM  
Feb-10-21 11:40AM  
07:51AM  
07:26AM  
06:15AM  
Feb-09-21 09:39AM  
06:27AM  
Feb-08-21 01:20PM  
08:56AM  
08:30AM  
08:22AM  
05:21AM  
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBIER REMIPresident and CEOJul 20Option Exercise20.232,80156,664326,652Jul 20 05:21 PM
BARBIER REMIPresident and CEOMay 27Option Exercise53.5556,0303,000,4061,134,885May 28 04:01 PM
ROBERTSON SANFORDDirectorMar 30Option Exercise40.897,472305,521920,095Mar 31 09:14 PM
FRIEDMANN NADAVChief Medical OfficerMar 17Option Exercise53.5528,0151,500,20392,428Mar 18 04:06 PM
O DONNELL MICHAEL JDirectorMar 16Option Exercise49.004,669228,7819,257Mar 18 03:59 PM
BARBIER REMIPresident and CEOSep 24Buy9.5910,00095,9001,078,855Sep 24 04:49 PM
ROBERTSON SANFORDDirectorSep 18Buy8.9236,281323,627912,623Sep 21 04:01 PM
Schoen EricChief Financial OfficerSep 17Buy7.042,00014,08027,300Sep 17 05:25 PM
Schoen EricChief Financial OfficerSep 17Buy7.0310,00070,30025,300Sep 17 05:25 PM
ROBERTSON SANFORDDirectorSep 17Buy6.98213,7191,491,759876,342Sep 17 05:15 PM